Daily close, T-120 (3/12/25) through T+5. Run-up high $9.71 on 8/18/25, low $5.43 on 4/16/25 (T-120 to T-1). FDA decision 8/27/25. Historical price action, not a forecast.
Positioning before the decision
On Aug 13, 2025, 14 days before the decision date, at-the-money options priced a move of ±12.2% through Aug 29, 2025 (the first listed expiry after the decision; ATM implied volatility 73%). The stock closed +1.1% at the first close across the decision and -1.3% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was Nuvaxovid - (2025-2026 Formula) approved by the FDA?
Yes. The FDA approved the application for Nuvaxovid - (2025-2026 Formula) on August 27, 2025. The primary source is linked on this page.
What was Nuvaxovid - (2025-2026 Formula) under FDA review for?
The application covered COVID-19 Vaccine. The FDA approved the application on August 27, 2025.
How did NVAX stock react to the FDA decision?
On the decision day NVAX moved +1.1%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.